Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05504681 · ClinicalTrials.gov registry record

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

A clinical trial of Neurocognitive Disorders, sponsored by Baptist Health South Florida.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT05504681: Recruiting study of Neurocognitive Disorders, sponsored by Baptist Health South Florida.

NCT05504681 is a study of Neurocognitive Disorders that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 200 participants, below the 581-participant average among 8 other Neurocognitive Disorders trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05504681, a study of Neurocognitive Disorders, is actively recruiting participants, sponsored by Baptist Health South Florida.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.

Primary Outcome

Learning and memory will be assessed by the number of correct responses (the total number of words correctly recalled). The "Verbal Recall" test will be used to measure the number of correct responses over 3 trials, the "Verbal Revision" will be used to measure the number of total correct responses, and the "Verbal Recognition" test will be used to measure number of correct responses minus the incorrect responses. Change is calculated as baseline score subtracted from post-baseline score over ti

Conditions Studied

Interventions

  • OTHER Observational study

Study Locations (1)

Florida

  • Miami Cancer Institute - Miami

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2021-11-30
Est. Completion 2027-11
Baptist Health South Florida

40 total trials

What NCT05504681 shows while recruiting

NCT05504681 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 581-participant average among 8 other Neurocognitive Disorders trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Neurocognitive Disorders appearing as the primary indexed condition, and to 1 intervention - of which Observational study is the first listed.

NCT05504681 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05504681 about?

NCT05504681 is a clinical study titled "Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic". This is prospective observational registry study that will assess 1) if the neurocognitive function app (Brainlab Cognition) can be used in a widespread neuro-oncology clinic setting and 2) if patient reported quality of life parameters can be obtained electronically and integrated into clinic.

What is the current status of trial NCT05504681?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2021-11-30. Estimated completion is 2027-11.

What conditions does trial NCT05504681 study?

This clinical trial studies the following conditions: Neurocognitive Disorders.

What interventions are being tested in trial NCT05504681?

The interventions under investigation include: Observational study (OTHER).

Who is sponsoring clinical trial NCT05504681?

This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05504681 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Neurocognitive Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05504681's enrollment target sits among peer trials

200 4th of 8 higher than 5 of 8 other Neurocognitive Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neurocognitive Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05504681, the US trial registry maintained by the National Library of Medicine. NCT05504681 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.